AI Protein Design Goes Big: Profluent's Lilly Deal Targets Large-Scale Gene Edits
nathanbenaich · x · 2026-08-11
VC Nathan Benaich discusses two main approaches in gene editing: fine-scale micro-edits (genetic scalpels) and large-scale kilobase payload insertions. He highlights AI protein design startup Profluent's deal with Eli Lilly as a prime example of the industry focusing on significant genetic payload integration.
More from Venture
- ZeroDrift Raises $10M Seed to Launch Command, an AI Compliance Firewall — Shruti_0810 · 2026-08-11
- Base44 Hit $1M ARR in Weeks, Acquired by Wix for $80M — petergyang · 2026-08-11
- How $1 of AI Spend Flows Through the Value Chain: iCapital Report — brucemacv · 2026-08-11
- Who Are the Token Brokers in the AI Compute Supply Chain? — thisguy123123 · 2026-08-11
- EA Funds Launches Transformative AI Fund, Replaces Long-Term Future Fund — AaronBergman18 · 2026-08-11
- Open-Source Model Customization Startup Trajectory Raises New Funding at $300M Valuation — steph_palazzolo · 2026-08-11